Multiple Myeloma, Bisphosphonate-Associated Osteonecrosis of the Jaw
Conditions
Interventions
This is a randomized, controlled, single-blind clinical study with cancer patients diagnosed with stage II and III periodontal disease using more than 3 doses of intravenous bisphosphonates. 30 patien
Sponsors
Faculdade de Odontologia de Ribeirão Preto da USP
Faculdade de Odontologia de Ribeirão Preto da USP
Eligibility
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Individuals of both sexes, adults or elderly, aged between 18 and 90 years who have undergone cancer treatment and received more than 3 doses of injectable bisphosphonates. Patients with bone metastases and multiple myeloma will be considered
Exclusion criteria
Exclusion criteria: Individuals will be excluded if they present any of the following conditions: (1) physical or mental illness at the time of the exam; (2) neurological disorders; (3) history of uncontrolled seizure or CNS or psychiatric disorder judged by the researchers to be clinically relevant before signing the informed consent form; (4) Who have undergone non-surgical periodontal therapy in the last six months before the study; (5) Patients previously submitted to head and neck radiotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to evaluate whether injectable fibrin-rich plasma associated with non-surgical periodontal therapy (TPNC) is more effective in the treatment of periodontal disease when compared to conventional TPNC in cancer patients using intravenous antiresorptive therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to evaluate the improvement in the clinical and radiographic parameters of periodontal disease through the analysis of the periogram comparatively before and after the proposed treatment of periodontal disease with i-PRF + TPNC, comparing parameters such as reduction in probing depth, bleeding on probing and gain insertion before and after each therapy. In addition to the reduction of pro-inflammatory cytokines in the gingival crevicular fluid, saliva and blood after the treatments carried out in both proposed groups. | — |
Countries
Brazil
Contacts
Public ContactLara Maria Innocentini
Universidade de São Paulo - Ribeirão Preto
Outcome results
None listed